Best of Ophthalmology Research: Updates in the Management of nAMD and DME

1.25 CME

75 MINS

SAVE

Overview

Provider Statement

This continuing education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Activity Description

Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing schedules, along with personalized treatment protocols utilizing FDA-approved therapies, have sought to address treatment burden while still providing visual acuity gains. In this CE activity, experts in the field review and discuss the latest clinical studies regarding therapies that provide durable improvements to visual and anatomic outcomes, and evaluate evidence-based and real-world studies demonstrating their application in the treatment of patients with nAMD and DME.

Target Audience

The intended audience for this activity is ophthalmologists and other healthcare professionals involved in the management of patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

Assess the latest evidence regarding therapies that improve visual and anatomic outcomes, as well as increased durability and real-world applications in the treatment of nAMD.
Examine key clinical findings from evidence-based and real-world studies that demonstrate durable vision gains and macular leakage control to optimize the treatment of DME.

Activity Chair

Arshad M. Khanani, MD, MA, FASRS
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, NV

Faculty

Roger A. Goldberg, MD, MBA
Vitreoretinal Specialist, Bay Area Retina Associates
Volunteer Faculty, CPMC
Walnut Creek, CA

Christina Y. Weng, MD, MBA
Professor of Ophthalmology
Fellowship Program Director, Vitreoretinal Diseases & Surgery
Baylor College of Medicine
Houston, TX

Planner/Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Accreditation

ACCME Jointly accredited In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, May 17, 2023, to May 16, 2024.

How to Participate in This Activity and Obtain CE Credit

To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Relationship information is accurate at the time of content development.

Activity Chair and Faculty report the following relevant financial relationship(s)

Roger A. Goldberg, MD, MBA
Consultant: AbbVie, Apellis, Boehringer Ingelheim, Coherus, EyePoint, Genentech/Roche, Outlook Therapeutics, Regeneron, Zeiss
Speaker Contracted by Ineligible Company: Apellis, Biogen, Genentech/Roche
Independent Research Contractor: AffaMed, Allergan, Apellis, Boehringer Ingelheim, EyePoint, Genentech/Roche, Janssen, Neurotech, Novo Nordisk

Arshad M. Khanani, MD, MA, FASRS
Consultant: 4DMT, Adverum, Alimera, Allergan, Apellis, AsclepiX, Aviceda, Bausch + Lomb, Broadwing Bio, Chengdu Kanghong, Cholgene, Gemini, Genentech, Glaukos, Graybug, Gyroscope, Iveric Bio, Janssen, Kato, Kodiak, Novartis, Oculis, Opthea, Oxurion, PolyPhotonix, RecensMedical, Regeneron, Retrotope, Regenxbio, RevOpsis, Roche, Unity Bio
Speaker Contracted by Ineligible Company: Allergan, Genentech, Novartis
Independent Research Contractor: 4DMT, Adverum, Apellis, AsclepiX, Chengdu Kanghong, Gemini, Genentech, Graybug, Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM, Novartis, Ocular Therapeutix, Oculis, Opthea, Oxurion, RecensMedical, Regenxbio, Roche, Unity Bio
Individual Stocks and Stock Options: Aviceda, PolyPhotonix, Recensmedical, Retrotope

Christina Y. Weng, MD, MBA
Consultant: Alcon, Alimera, Allergan/AbbVie, EyePoint, Genentech, Iveric Bio, Novartis, Regeneron, Regenxbio
Independent Research Contractor: Alimera, AGTC, DRCR Retina Network

Planner/Reviewer reports the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.